26 Jul Investor Spotlight: Ridgeline Therapeutics – A Versant Ventures Discovery Engine
Ridgeline Therapeutics is Versant’s newest discovery engine aimed at translating new opportunities from academics into industry quality therapeutic candidates. Based in Basel, this central European location allows for privileged access to both strong academic research as well as large pharmaceutical partners. Alex Mayweg will provide a deeper look into Ridgeline’s approach on company creation, drug discovery and portfolio successes. Participants will also learn about Ridgeline’s collaborations with academics and pharma companies.
When: 18.09.2019, 19:00 – 21:00
Where: Halle 7, Gundeldingerfeld, Dornacherstrasse 192, 4053 Basel
Participation to the event is free of charge; however, your registration by 16th September 2019 is kindly required.
18:30 Door Opening
19:05 Dr. Alex Mayweg, President of Ridgeline Therapeutics, Partner at Versant Ventures
20:00 Networking Apero